BlackRock, Inc. Amends Schedule 13G for Cidara Therapeutics, Inc.

BlackRock, Inc. has filed an amendment to its Schedule 13G for Cidara Therapeutics, Inc., reporting a decrease in its ownership stake. As of September 30, 2025, BlackRock owns 1,163,607 shares of Cidara Therapeutics' common stock, representing a 4.6% ownership stake. This marks a significant decrease from its previous holdings, with a reduction of 8,050,993 shares and a value decrease of $9,348,491,031.88. The filing indicates that BlackRock's ownership is now below the 5% threshold, and it certifies that the shares were not acquired for the purpose of influencing the control of the issuer. The amendment was signed by Spencer Fleming, Managing Director of BlackRock, Inc.